Recent Developments in Stem and Progenitor Cell Therapy for Cardiac Repair

Circulation Research

Volumn 119, Issue 12, 2016, Pages e152-e159

  Zhao, John ^a   Ghafghazi, Shahab ^a   Khan, Abdur Rahman ^a   Farid, Talha Ahmad ^a   Moore, Joseph B ^a  

^a University of Louisville School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE;

ARTICLE; CELL THERAPY; EXOSOME; HEART SURGERY; HUMAN; MULTICENTER STUDY (TOPIC); NONHUMAN; PARACRINE SIGNALING; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); STEM CELL TRANSPLANTATION; ANIMAL; CARDIAC MUSCLE CELL; HEART DISEASE; HEMATOPOIETIC STEM CELL; PATHOPHYSIOLOGY; PHYSIOLOGY; PROCEDURES; REGENERATION; TRANSPLANTATION; TRENDS;

ANIMALS; HEART DISEASES; HEMATOPOIETIC STEM CELLS; HUMANS; MYOCYTES, CARDIAC; REGENERATION; STEM CELL TRANSPLANTATION;

EID: 85002661921     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.116.310257     Document Type: Article

References (101)

1. Mozaffarian D, Benjamin EJ, Go AS, et al; Writing Group Members; American Heart Association Statistics Committee; Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics-2016 Update: a report from the American Heart Association. Circulation. 2016;133:e38-e360. doi: 10. 1161/CIR. 0000000000000350.
2. Ghafghazi S, Wysoczynski M, Keith MCL, Moore J IV, Bolli R. Ventricular remodeling: the appropriate surrogate end point for cell-based therapy. Dialogues Cardiovasc Med 2015;20:126-138.
3. Beltrami AP, Barlucchi L, Torella D, Baker M, Limana F, Chimenti S, Kasahara H, Rota M, Musso E, Urbanek K, Leri A, Kajstura J, Nadal-Ginard B, Anversa P. Adult cardiac stem cells are multipotent and support myocardial regeneration. Cell. 2003;114:763-776.
4. Schächinger V, Erbs S, Elsässer A, Haberbosch W, Hambrecht R, Hölschermann H, Yu J, Corti R, Mathey DG, Hamm CW, Süselbeck T, Assmus B, Tonn T, Dimmeler S, Zeiher AM; REPAIR-AMI Investigators. Intracoronary bone marrow-derived progenitor cells in acute myocardial infarction. N Engl J Med. 2006;355:1210-1221. doi: 10. 1056/NEJMoa060186.
5. Schächinger V, Erbs S, Elsässer A, et al; REPAIR-AMI Investigators. Improved clinical outcome after intracoronary administration of bonemarrow-derived progenitor cells in acute myocardial infarction: final 1-year results of the REPAIR-AMI trial. Eur Heart J. 2006;27:2775-2783. doi: 10. 1093/eurheartj/ehl388.
6. Hare JM, Traverse JH, Henry TD, Dib N, Strumpf RK, Schulman SP, Gerstenblith G, DeMaria AN, Denktas AE, Gammon RS, Hermiller JB Jr, Reisman MA, Schaer GL, Sherman W. A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction. J Am Coll Cardiol. 2009;54:2277-2286. doi: 10. 1016/j. jacc. 2009. 06. 055.
7. Hare JM, Fishman JE, Gerstenblith G, et al. Comparison of allogeneic vs autologous bone marrow-derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial. JAMA. 2012;308:2369-2379. doi: 10. 1001/ jama. 2012. 25321.
8. Karantalis V, DiFede DL, Gerstenblith G, et al. Autologous mesenchymal stem cells produce concordant improvements in regional function, tissue perfusion, and fibrotic burden when administered to patients undergoing coronary artery bypass grafting: The Prospective Randomized Study of Mesenchymal Stem Cell Therapy in Patients Undergoing Cardiac Surgery (PROMETHEUS) trial. Circ Res. 2014;114:1302-1310. doi: 10. 1161/ CIRCRESAHA. 114. 303180.
9. Karantalis V, Hare JM. Use of mesenchymal stem cells for therapy of cardiac disease. Circ Res. 2015;116:1413-1430. doi: 10. 1161/ CIRCRESAHA. 116. 303614.
10. Sanina C, Hare JM. Mesenchymal stem cells as a biological drug for heart disease: where are we with cardiac cell-based therapy? Circ Res. 2015;117:229-233. doi: 10. 1161/CIRCRESAHA. 117. 306306.
11. Bartunek J, Vanderheyden M, Vandekerckhove B, Mansour S, De Bruyne B, De Bondt P, Van Haute I, Lootens N, Heyndrickx G, Wijns W. Intracoronary injection of CD133-positive enriched bone marrow progenitor cells promotes cardiac recovery after recent myocardial infarction: feasibility and safety. Circulation. 2005;112:I178-I183. doi: 10. 1161/ CIRCULATIONAHA. 104. 522292.
12. Stamm C, Kleine HD, Choi YH, Dunkelmann S, Lauffs JA, Lorenzen B, David A, Liebold A, Nienaber C, Zurakowski D, Freund M, Steinhoff G. Intramyocardial delivery of CD133+ bone marrow cells and coronary artery bypass grafting for chronic ischemic heart disease: safety and efficacy studies. J Thorac Cardiovasc Surg. 2007;133:717-725. doi: 10. 1016/j. jtcvs. 2006. 08. 077.
13. Singla DK, Long X, Glass C, Singla RD, Yan B. Induced pluripotent stem (iPS) cells repair and regenerate infarcted myocardium. Mol Pharm. 2011;8:1573-1581. doi: 10. 1021/mp2001704.
14. Pasha Z, Haider HKh, Ashraf M. Efficient non-viral reprogramming of myoblasts to stemness with a single small molecule to generate cardiac progenitor cells. PLoS One. 2011;6:e23667. doi: 10. 1371/journal. pone. 0023667.
15. Ye L, Chang YH, Xiong Q, et al. Cardiac repair in a porcine model of acute myocardial infarction with human induced pluripotent stem cell-derived cardiovascular cells. Cell Stem Cell. 2014;15:750-761. doi: 10. 1016/j. stem. 2014. 11. 009.
16. Hodgson DM, Behfar A, Zingman LV, Kane GC, Perez-Terzic C, Alekseev AE, Pucéat M, Terzic A. Stable benefit of embryonic stem cell therapy in myocardial infarction. Am J Physiol Heart Circ Physiol. 2004;287:H471-H479. doi: 10. 1152/ajpheart. 01247. 2003.
17. Singla DK, Lyons GE, Kamp TJ. Transplanted embryonic stem cells following mouse myocardial infarction inhibit apoptosis and cardiac remodeling. Am J Physiol Heart Circ Physiol. 2007;293:H1308-H1314. doi 10. 1152/ajpheart. 01277. 2006.
18. Chong JJ, Yang X, Don CW, et al. Human embryonic-stem-cell-derived cardiomyocytes regenerate non-human primate hearts. Nature. 2014;510:273-277. doi: 10. 1038/nature13233.
19. Laflamme MA, Chen KY, Naumova AV, et al. Cardiomyocytes derived from human embryonic stem cells in pro-survival factors enhance function of infarcted rat hearts. Nat Biotechnol. 2007;25:1015-1024. doi: 10. 1038/nbt1327.
20. Avolio E, Meloni M, Spencer HL, et al. Combined intramyocardial delivery of human pericytes and cardiac stem cells additively improves the healing of mouse infarcted hearts through stimulation of vascular and muscular repair. Circ Res. 2015;116:e81-e94. doi: 10. 1161/ CIRCRESAHA. 115. 306146.
21. Furtado MB, Costa MW, Pranoto EA, Salimova E, Pinto AR, Lam NT, Park A, Snider P, Chandran A, Harvey RP, Boyd R, Conway SJ, Pearson J, Kaye DM, Rosenthal NA. Cardiogenic genes expressed in cardiac fibroblasts contribute to heart development and repair. Circ Res. 2014;114:1422-1434. doi: 10. 1161/CIRCRESAHA. 114. 302530.
22. Keith MC, Bolli R. "String theory" of c-kit(pos) cardiac cells: a new paradigm regarding the nature of these cells that may reconcile apparently discrepant results. Circ Res. 2015;116:1216-1230. doi: 10. 1161/ CIRCRESAHA. 116. 305557.
23. Torella D, Ellison GM, Nadal-Ginard B. Adult c-kit(pos) cardiac stem cells fulfill Koch's postulates as causal agents for cardiac regeneration. Circ Res. 2014;114:e24-e26. doi: 10. 1161/CIRCRESAHA. 113. 303313.
24. Ellison GM, Vicinanza C, Smith AJ, et al. Adult c-kit(pos) cardiac stem cells are necessary and sufficient for functional cardiac regeneration and repair. Cell. 2013;154:827-842. doi: 10. 1016/j. cell. 2013. 07. 039.
25. Kim PJ, Mahmoudi M, Ge X, Matsuura Y, Toma I, Metzler S, Kooreman NG, Ramunas J, Holbrook C, McConnell MV, Blau H, Harnish P, Rulifson E, Yang PC. Direct evaluation of myocardial viability and stem cell engraftment demonstrates salvage of the injured myocardium. Circ Res. 2015;116:e40-e50. doi: 10. 1161/CIRCRESAHA. 116. 304668.
26. Mohsin S, Troupes CD, Starosta T, Sharp TE, Agra EJ, Smith S, Duran JM, Zalavadia N, Zhou Y, Kubo H, Berretta RM, Houser SR. Unique features of cortical bone stem cells associated with repair of the injured heart. Circ Res. 2015;117:1024-1033. doi: 10. 1161/CIRCRESAHA. 115. 307362.
27. Weil BR, Suzuki G, Leiker MM, Fallavollita JA, Canty JM Jr. Comparative efficacy of intracoronary allogeneic mesenchymal stem cells and cardiosphere-derived cells in swine with hibernating myocardium. Circ Res. 2015;117:634-644. doi: 10. 1161/CIRCRESAHA. 115. 306850.
28. Quijada P, Salunga HT, Hariharan N, Cubillo JD, El-Sayed FG, Moshref M, Bala KM, Emathinger JM, De La Torre A, Ormachea L, Alvarez R Jr, Gude NA, Sussman MA. Cardiac stem cell hybrids enhance myocardial repair. Circ Res. 2015;117:695-706. doi: 10. 1161/CIRCRESAHA. 115. 306838.
29. Li TS, Cheng K, Malliaras K, Smith RR, Zhang Y, Sun B, Matsushita N, Blusztajn A, Terrovitis J, Kusuoka H, Marbán L, Marbán E. Direct comparison of different stem cell types and subpopulations reveals superior paracrine potency and myocardial repair efficacy with cardiosphere-derived cells. J Am Coll Cardiol. 2012;59:942-953. doi: 10. 1016/j. jacc. 2011. 11. 029.
30. Williams AR, Hatzistergos KE, Addicott B, McCall F, Carvalho D, Suncion V, Morales AR, Da Silva J, Sussman MA, Heldman AW, Hare JM. Enhanced effect of combining human cardiac stem cells and bone marrow mesenchymal stem cells to reduce infarct size and to restore cardiac function after myocardial infarction. Circulation. 2013;127:213-223. doi: 10. 1161/CIRCULATIONAHA. 112. 131110.
31. Bolli R, Ghafghazi S. Cell therapy needs rigorous translational studies in large animal models. J Am Coll Cardiol. 2015;66:2000-2004. doi 10. 1016/j. jacc. 2015. 09. 002.
32. Wysoczynski M, Dassanayaka S, Zafir A, Ghafghazi S, Long BW, Noble C, DeMartino AM, Brittian KR, Bolli R, Jones SP. A new method to stabilize c-kit expression in reparative cardiac mesenchymal cells. Front Cell Dev Biol. 2016;4:78. doi: 10. 3389/fcell. 2016. 00078.
33. Zhang Y, Cao N, Huang Y, Spencer CI, Fu JD, Yu C, Liu K, Nie B, Xu T, Li K, Xu S, Bruneau BG, Srivastava D, Ding S. Expandable cardiovascular progenitor cells reprogrammed from fibroblasts. Cell Stem Cell. 2016;18:368-381. doi: 10. 1016/j. stem. 2016. 02. 001.
34. Moore JB 4th, Zhao J, Keith MC, Amraotkar AR, Wysoczynski M, Hong KU and Bolli R. The Epigenetic regulator HDAC1 modulates transcription of a core cardiogenic program in human cardiac mesenchymal stromal cells through a p53-dependent mechanism. Stem cells. 2016. doi: 10. 1002/ stem. 2471.
35. Wang H, Cao N, Spencer CI, Nie B, Ma T, Xu T, Zhang Y, Wang X, Srivastava D, Ding S. Small molecules enable cardiac reprogramming of mouse fibroblasts with a single factor, Oct4. Cell Rep. 2014;6:951-960. doi: 10. 1016/j. celrep. 2014. 01. 038.
36. Willems E, Mercola M. Reprogramming the cardiac field. Circ Res. 2014;114:409-411. doi: 10. 1161/CIRCRESAHA. 113. 302946.
37. Feaster TK, Cadar AG, Wang L, Williams CH, Chun YW, Hempel JE, Bloodworth N, Merryman WD, Lim CC, Wu JC, Knollmann BC, Hong CC. Matrigel Mattress: a method for the generation of single contracting human-induced pluripotent stem cell-derived cardiomyocytes. Circ Res. 2015;117:995-1000. doi: 10. 1161/CIRCRESAHA. 115. 307580.
38. Lalit PA, Hei DJ, Raval AN, Kamp TJ. Induced pluripotent stem cells for post-myocardial infarction repair: remarkable opportunities and challenges. Circ Res. 2014;114:1328-1345. doi: 10. 1161/ CIRCRESAHA. 114. 300556.
39. Nagata N, Yamanaka S. Perspectives for induced pluripotent stem cell technology: new insights into human physiology involved in somatic mosaicism. Circ Res. 2014;114:505-510. doi: 10. 1161/CIRCRESAHA. 114. 303043.
40. Yang X, Pabon L, Murry CE. Engineering adolescence: maturation of human pluripotent stem cell-derived cardiomyocytes. Circ Res. 2014;114:511-523. doi: 10. 1161/CIRCRESAHA. 114. 300558.
41. Karakikes I, Ameen M, Termglinchan V, Wu JC. Human induced pluripotent stem cell-derived cardiomyocytes: insights into molecular, cellular, and functional phenotypes. Circ Res. 2015;117:80-88. doi: 10. 1161/ CIRCRESAHA. 117. 305365.
42. Hodgkinson CP, Gomez JA, Payne AJ, Zhang L, Wang X, Dal-Pra S, Pratt RE, Dzau VJ. Abi3bp regulates cardiac progenitor cell proliferation and differentiation. Circ Res. 2014;115:1007-1016. doi: 10. 1161/ CIRCRESAHA. 115. 304216.
43. Paige SL, Plonowska K, Xu A, Wu SM. Molecular regulation of cardiomyocyte differentiation. Circ Res. 2015;116:341-353. doi: 10. 1161/ CIRCRESAHA. 116. 302752.
44. Cao N, Liu Z, Chen Z, Wang J, Chen T, Zhao X, Ma Y, Qin L, Kang J, Wei B, Wang L, Jin Y, Yang HT. Ascorbic acid enhances the cardiac differentiation of induced pluripotent stem cells through promoting the proliferation of cardiac progenitor cells. Cell Res. 2012;22:219-236. doi: 10. 1038/cr. 2011. 195.
45. Boland MJ, Nazor KL, Loring JF. Epigenetic regulation of pluripotency and differentiation. Circ Res. 2014;115:311-324. doi: 10. 1161/ CIRCRESAHA. 115. 301517.
46. Eom GH, Nam YS, Oh JG, Choe N, Min HK, Yoo EK, Kang G, Nguyen VH, Min JJ, Kim JK, Lee IK, Bassel-Duby R, Olson EN, Park WJ, Kook H. Regulation of acetylation of histone deacetylase 2 by p300 CBP-associated factor/histone deacetylase 5 in the development of cardiac hypertrophy. Circ Res. 2014;114:1133-1143. doi: 10. 1161/ CIRCRESAHA. 114. 303429.
47. Felician G, Collesi C, Lusic M, Martinelli V, Ferro MD, Zentilin L, Zacchigna S, Giacca M. Epigenetic modification at Notch responsive promoters blunts efficacy of inducing notch pathway reactivation after myocardial infarction. Circ Res. 2014;115:636-649. doi: 10. 1161/ CIRCRESAHA. 115. 304517.
48. Preissl S, Schwaderer M, Raulf A, Hesse M, Grüning BA, Köbele C, Backofen R, Fleischmann BK, Hein L, Gilsbach R. Deciphering the epigenetic code of cardiac myocyte transcription. Circ Res. 2015;117:413-423. doi: 10. 1161/CIRCRESAHA. 115. 306337.
49. Khan AR, Farid TA, Pathan A, Tripathi A, Ghafghazi S, Wysoczynski M, Bolli R. Impact of cell therapy on myocardial perfusion and cardiovascular outcomes in patients with angina refractory to medical therapy: a systematic review and meta-analysis. Circ Res. 2016;118:984-993. doi 10.1161/CIRCRESAHA. 115. 308056.
50. Hong KU, Guo Y, Li QH, Cao P, Al-Maqtari T, Vajravelu BN, Du J, Book MJ, Zhu X, Nong Y, Bhatnagar A, Bolli R. c-kit+ Cardiac stem cells alleviate post-myocardial infarction left ventricular dysfunction despite poor engraftment and negligible retention in the recipient heart. PLoS One. 2014;9:e96725. doi: 10. 1371/journal. pone. 0096725.
51. Gnecchi M, Zhang Z, Ni A, Dzau VJ. Paracrine mechanisms in adult stem cell signaling and therapy. Circ Res. 2008;103:1204-1219. doi: 10. 1161/ CIRCRESAHA. 108. 176826.
52. Takahashi M, Li TS, Suzuki R, Kobayashi T, Ito H, Ikeda Y, Matsuzaki M, Hamano K. Cytokines produced by bone marrow cells can contribute to functional improvement of the infarcted heart by protecting cardiomyocytes from ischemic injury. Am J Physiol Heart Circ Physiol. 2006;291:H886-H893. doi: 10. 1152/ajpheart. 00142. 2006.
53. Yellon DM, Davidson SM. Exosomes: nanoparticles involved in cardioprotection? Circ Res. 2014;114:325-332. doi: 10. 1161/ CIRCRESAHA. 113. 300636.
54. Hodgkinson CP, Kang MH, Dal-Pra S, Mirotsou M, Dzau VJ. MicroRNAs and cardiac regeneration. Circ Res. 2015;116:1700-1711. doi: 10. 1161/ CIRCRESAHA. 116. 304377.
55. Waldenström A, Ronquist G. Role of exosomes in myocardial remodeling. Circ Res. 2014;114:315-324. doi: 10. 1161/CIRCRESAHA. 114. 300584.
56. Angoulvant D, Ivanes F, Ferrera R, Matthews PG, Nataf S, Ovize M. Mesenchymal stem cell conditioned media attenuates in vitro and ex vivo myocardial reperfusion injury. J Heart Lung Transplant. 2011;30:95-102. doi: 10. 1016/j. healun. 2010. 08. 023.
57. Gnecchi M, He H, Liang OD, Melo LG, Morello F, Mu H, Noiseux N, Zhang L, Pratt RE, Ingwall JS, Dzau VJ. Paracrine action accounts for marked protection of ischemic heart by Akt-modified mesenchymal stem cells. Nat Med. 2005;11:367-368. doi: 10. 1038/nm0405-367.
58. Gnecchi M, He H, Noiseux N, Liang OD, Zhang L, Morello F, Mu H, Melo LG, Pratt RE, Ingwall JS, Dzau VJ. Evidence supporting paracrine hypothesis for Akt-modified mesenchymal stem cell-mediated cardiac protection and functional improvement. FASEB J. 2006;20:661-669. doi 10. 1096/fj. 05-5211com.
59. Liang X, Ding Y, Zhang Y, Tse HF, Lian Q. Paracrine mechanisms of mesenchymal stem cell-based therapy: current status and perspectives. Cell Transplant. 2014;23:1045-1059. doi: 10. 3727/096368913X667709.
60. Kofler S, Nickel T, Weis M. Role of cytokines in cardiovascular diseases: a focus on endothelial responses to inflammation. Clin Sci (Lond). 2005;108:205-213. doi: 10. 1042/CS20040174.
61. Losordo DW, Dimmeler S. Therapeutic angiogenesis and vasculogenesis for ischemic disease. Part I: angiogenic cytokines. Circulation. 2004;109:2487-2491. doi: 10. 1161/01. CIR. 0000128595. 79378. FA.
62. Ranganath SH, Levy O, Inamdar MS, Karp JM. Harnessing the mesenchymal stem cell secretome for the treatment of cardiovascular disease. Cell Stem Cell. 2012;10:244-258. doi: 10. 1016/j. stem. 2012. 02. 005.
63. Vandervelde S, van Luyn MJ, Tio RA, Harmsen MC. Signaling factors in stem cell-mediated repair of infarcted myocardium. J Mol Cell Cardiol. 2005;39:363-376. doi: 10. 1016/j. yjmcc. 2005. 05. 012.
64. Burchfield JS, Dimmeler S. Role of paracrine factors in stem and progenitor cell mediated cardiac repair and tissue fibrosis. Fibrogenesis Tissue Repair. 2008;1:4. doi: 10. 1186/1755-1536-1-4.
65. Sluijter JP, van Rooij E. Exosomal microRNA clusters are important for the therapeutic effect of cardiac progenitor cells. Circ Res. 2015;116:219-221. doi: 10. 1161/CIRCRESAHA. 114. 305673.
66. Sahoo S, Klychko E, Thorne T, Misener S, Schultz KM, Millay M, Ito A, Liu T, Kamide C, Agrawal H, Perlman H, Qin G, Kishore R, Losordo DW. Exosomes from human CD34(+) stem cells mediate their proangiogenic paracrine activity. Circ Res. 2011;109:724-728. doi 10. 1161/CIRCRESAHA. 111. 253286.
67. Gray WD, French KM, Ghosh-Choudhary S, Maxwell JT, Brown ME, Platt MO, Searles CD, Davis ME. Identification of therapeutic covariant microRNA clusters in hypoxia-treated cardiac progenitor cell exosomes using systems biology. Circ Res. 2015;116:255-263. doi: 10. 1161/ CIRCRESAHA. 116. 304360.
68. Ibrahim AG, Cheng K, Marbán E. Exosomes as critical agents of cardiac regeneration triggered by cell therapy. Stem Cell Reports. 2014;2:606-619. doi: 10. 1016/j. stemcr. 2014. 04. 006.
69. Barile L, Lionetti V, Cervio E, Matteucci M, Gherghiceanu M, Popescu LM, Torre T, Siclari F, Moccetti T, Vassalli G. Extracellular vesicles from human cardiac progenitor cells inhibit cardiomyocyte apoptosis and improve cardiac function after myocardial infarction. Cardiovasc Res. 2014;103:530-541. doi: 10. 1093/cvr/cvu167.
70. Khan M, Nickoloff E, Abramova T, et al. Embryonic stem cell-derived exosomes promote endogenous repair mechanisms and enhance cardiac function following myocardial infarction. Circ Res. 2015;117:52-64. doi 10 .1161/CIRCRESAHA. 117. 305990.
71. Ong SG, Wu JC. Exosomes as potential alternatives to stem cell therapy in mediating cardiac regeneration. Circ Res. 2015;117:7-9. doi: 10. 1161/ CIRCRESAHA. 115. 306593.
72. Krane M, Deutsch MA, Doppler S, Lange R, Wu SM. Small RNAs make big impact in cardiac repair. Circ Res. 2015;116:393-395. doi: 10. 1161/ CIRCRESAHA. 114. 305676.
73. Dimmeler S, Ylä-Herttuala S. 14q32 miRNA cluster takes center stage in neovascularization. Circ Res. 2014;115:680-682. doi: 10. 1161/ CIRCRESAHA. 114. 304973.
74. Castaldi A, Zaglia T, Di Mauro V, et al. MicroRNA-133 modulates the 1-adrenergic receptor transduction cascade. Circ Res. 2014;115:273-283. doi: 10. 1161/CIRCRESAHA. 115. 303252.
75. Yu B, Kim HW, Gong M, Wang J, Millard RW, Wang Y, Ashraf M, Xu M. Exosomes secreted from GATA-4 overexpressing mesenchymal stem cells serve as a reservoir of anti-apoptotic microRNAs for cardioprotection. Int J Cardiol. 2015;182:349-360. doi: 10. 1016/j. ijcard. 2014. 12. 043.
76. Liu J, van Mil A, Vrijsen K, Zhao J, Gao L, Metz CH, Goumans MJ, Doevendans PA, Sluijter JP. MicroRNA-155 prevents necrotic cell death in human cardiomyocyte progenitor cells via targeting RIP1. J Cell Mol Med. 2011;15:1474-1482. doi: 10. 1111/j. 1582-4934. 2010. 01104. x.
77. Gladka MM, van Rooij E. AntimiR-34a to enhance cardiac repair after ischemic injury. Circ Res. 2015;117:395-397. doi: 10. 1161/ CIRCRESAHA. 115. 307066.
78. Yang Y, Cheng HW, Qiu Y, Dupee D, Noonan M, Lin YD, Fisch S, Unno K, Sereti KI, Liao R. MicroRNA-34a plays a key role in cardiac repair and regeneration following myocardial infarction. Circ Res. 2015;117:450-459. doi: 10. 1161/CIRCRESAHA. 117. 305962.
79. Jayawardena TM, Finch EA, Zhang L, Zhang H, Hodgkinson CP, Pratt RE, Rosenberg PB, Mirotsou M, Dzau VJ. MicroRNA induced cardiac reprogramming in vivo: evidence for mature cardiac myocytes and improved cardiac function. Circ Res. 2015;116:418-424. doi: 10. 1161/ CIRCRESAHA. 116. 304510.
80. Wang D, Zhang H, Li M, Frid MG, Flockton AR, McKeon BA, Yeager ME, Fini MA, Morrell NW, Pullamsetti SS, Velegala S, Seeger W, McKinsey TA, Sucharov CC, Stenmark KR. MicroRNA-124 controls the proliferative, migratory, and inflammatory phenotype of pulmonary vascular fibroblasts. Circ Res. 2014;114:67-78. doi: 10. 1161/ CIRCRESAHA. 114. 301633.
81. Schoolmeesters A, Eklund T, Leake D, Vermeulen A, Smith Q, Force Aldred S, Fedorov Y. Functional profiling reveals critical role for miRNA in differentiation of human mesenchymal stem cells. PLoS One. 2009;4:e5605. doi: 10. 1371/journal. pone. 0005605.
82. Piubelli C, Meraviglia V, Pompilio G, D'Alessandra Y, Colombo GI, Rossini A. microRNAs and Cardiac Cell Fate. Cells. 2014;3:802-823. doi 10. 3390/cells3030802.
83. Fisher SA, Zhang H, Doree C, Mathur A, Martin-Rendon E. Stem cell treatment for acute myocardial infarction. Cochrane Database Syst Rev. 2015:CD006536.
84. Gyöngyösi M, Wojakowski W, Lemarchand P, et al; ACCRUE Investigators. Meta-Analysis of Cell-based CaRdiac stUdiEs (ACCRUE) in patients with acute myocardial infarction based on individual patient data. Circ Res. 2015;116:1346-1360. doi: 10. 1161/CIRCRESAHA. 116. 304346.
85. Fisher SA, Doree C, Mathur A, Martin-Rendon E. Meta-analysis of cell therapy trials for patients with heart failure. Circ Res. 2015;116:1361-1377. doi: 10. 1161/CIRCRESAHA. 116. 304386.
86. de Jong R, Houtgraaf JH, Samiei S, Boersma E, Duckers HJ. Intracoronary stem cell infusion after acute myocardial infarction: a meta-analysis and update on clinical trials. Circ Cardiovasc Interv. 2014;7:156-167. doi 10. 1161/CIRCINTERVENTIONS. 113. 001009.
87. Delewi R, Andriessen A, Tijssen JG, Zijlstra F, Piek JJ, Hirsch A. Impact of intracoronary cell therapy on left ventricular function in the setting of acute myocardial infarction: a meta-analysis of randomised controlled clinical trials. Heart. 2013;99:225-232. doi: 10. 1136/heartjnl-2012-302230.
88. Pompilio G, Nigro P, Bassetti B, Capogrossi MC. Bone marrow cell therapy for ischemic heart disease: the never ending story. Circ Res. 2015;117:490-493. doi: 10. 1161/CIRCRESAHA. 115. 307184.
89. Afzal MR, Samanta A, Shah ZI, Jeevanantham V, Abdel-Latif A, Zuba-Surma EK, Dawn B. Adult bone marrow cell therapy for ischemic heart disease: evidence and insights from randomized controlled trials. Circ Res. 2015;117:558-575. doi: 10. 1161/CIRCRESAHA. 114. 304792.
90. Jeevanantham V, Butler M, Saad A, Dawn B, Abdel-Latif A, Zuba-Surma EK. Response to letter regarding article, "Adult bone marrow cell therapy improves survival and induces long-term improvement in cardiac parameters: a systematic review and meta-analysis". Circulation. 2013;127:e548.
91. Kovacic JC, Fuster V. Cell therapy for patients with acute myocardial infarction: ACCRUEd evidence to date. Circ Res. 2015;116:1287-1290. doi 10. 1161/CIRCRESAHA. 115. 306323.
92. Martin-Rendon E. Meta-analyses of human cell-based cardiac regeneration therapies: what can systematic reviews tell us about cell therapies for ischemic heart disease? Circ Res. 2016;118:1264-1272. doi: 10. 1161/ CIRCRESAHA. 115. 307540.
93. Gao LR, Chen Y, Zhang NK, et al. Intracoronary infusion of Wharton's jelly-derived mesenchymal stem cells in acute myocardial infarction: double-blind, randomized controlled trial. BMC Med. 2015;13:162. doi: 10. 1186/s12916-015-0399-z.
94. Patel AN, Henry TD, Quyyumi AA, Schaer GL, Anderson RD, Toma C, East C, Remmers AE, Goodrich J, Desai AS, Recker D, DeMaria A; ixCELL-DCM Investigators. Ixmyelocel-T for patients with ischaemic heart failure: a prospective randomised double-blind trial. Lancet. 2016;387:2412-2421. doi: 10. 1016/S0140-6736(16)30137-4.
95. Henry TD, Traverse JH, Hammon BL, East CA, Bruckner B, Remmers AE, Recker D, Bull DA, Patel AN. Safety and efficacy of ixmyelocel-T: an expanded, autologous multi-cellular therapy, in dilated cardiomyopathy. Circ Res. 2014;115:730-737. doi: 10. 1161/CIRCRESAHA. 115. 304554.
96. Bartunek J. CHART-1: Phase 3 congestive heart failure cardiopoietic regenerative therapy. European Society of Cardiology Congress 2016; Rome, Italy. August 28, 2016; Abstract 1229.
97. Perin EC, Borow KM, Silva GV, DeMaria AN, Marroquin OC, Huang PP, Traverse JH, Krum H, Skerrett D, Zheng Y, Willerson JT, Itescu S, Henry TD. A phase II dose-escalation study of allogeneic mesenchymal precursor cells in patients with ischemic or nonischemic heart failure. Circ Res. 2015;117:576-584. doi: 10. 1161/CIRCRESAHA. 115. 306332.
98. Assmus B, Dimmeler S, Zeiher AM. Cardiac cell therapy: lost in metaanalyses. Circ Res. 2015;116:1291-1292. doi: 10. 1161/CIRCRESAHA. 115. 306330.
99. Tokita Y, Tang X-L, Li Q, Wysoczynski M, Hong KY, Nakamura S, Wu W-J, Xie W, Li D, Hunt G, Ou Q, Stowers H, Bolli R. Repeated administrations of cardiac progenitor cells are markedly more effective than a single administration. Circ Res. 2016;119:635-651. doi: 10. 1161/ CIRCRESAHA. 116. 308937
100. Assmus B, Alakmeh S, De Rosa S, Bönig H, Hermann E, Levy WC, Dimmeler S, Zeiher AM. Improved outcome with repeated intracoronary injection of bone marrow-derived cells within a registry: rationale for the randomized outcome trial REPEAT. Eur Heart J. 2016;37:1659-1666. doi: 10. 1093/eurheartj/ehv559.
101. Karantalis V, Suncion-Loescher VY, Bagno L, et al. Synergistic Effects of Combined Cell Therapy for Chronic Ischemic Cardiomyopathy. J Am Coll Cardiol. 2015;66:1990-1999. doi: 10. 1016/j. jacc. 2015. 08. 879.